1Y Target$50.15Near-term target
5Y Target$49.18Compound horizon
10Y Target$62.77Long-dated conviction
FCF$1.6bTTM · 03/26C+FCF $1.6b — respectable but not differentiating · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev+34.3%TTM YoYARevenue +34.3% — hypergrowth, top decile
D/E0.58B+D/E 0.58 — healthy leverage, well below danger zone
P/E11.9xA-P/E 11.9 — cheap relative to market and most sectors
PEG0.66A-PEG 0.66 — strong; Lynch's preferred zone
Why now
Oil & Gas E&P · market cap $11.4b. 20% off the 52-week high of $45.75. Revenue growing +34% — in hypergrowth territory. PEG 0.66 — paying under fair value for the growth rate. 20 sell-side analysts rate this a Buy with a mean 1-yr target of $50.15 (implying +36% upside).
Moat
Net margin 17% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 13% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 171% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Jurisdictional + permitting risk — mining and extraction operations concentrate exposure to political stability, royalty regimes, and environmental review timelines that can stall production for years.
Horizon
1-3 yr $50.15 (20-analyst consensus) — multiple re-rating thesis requires a catalyst. 5 yr $49.18 at ~6% CAGR — dividend + buyback compounding. 10 yr $62.77 if the moat survives secular pressure.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See
terms and
methodology for full disclosures.